NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-19-364 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical and preclinical/non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.
Funding Opportunity RFA-OD-19-025 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA), issued by the Office of the Director (OD), National Institutes of Health (NIH), is to invite applications from entities/institutions in Institutional Development Award (IDeA)-eligible States to participate in the Environmental Influences on Child Health Outcomes (ECHO) IDeA States Pediatric Clinical Trials Network (ISPCTN) as the Data Coordination and Operations Center (DCOC). The DCOC will support the Clinical Sites of the ISPCTN to: --Conduct multicenter clinical trials research, assuring the participation of children living in rural or underserved communities located in Institutional Development Award (IDeA) states. --Build pediatric research capacity for IDeA states to support the conduct of clinical trials of relevance to rural or underserved children in IDeA states.
Funding Opportunity RFA-OD-19-026 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA), issued by the Office of the Director (OD), National Institutes of Health (NIH), is to invite applications from entities/institutions in Institutional Development Award (IDeA)-eligible States to participate in the Environmental Influences on Child Health Outcomes (ECHO) IDeA States Pediatric Clinical Trials Network (ISPCTN) as a Clinical Site. The Clinical Sites of the ISPCTN will: --Conduct multicenter clinical trials research, assuring the participation of children living in rural or underserved communities located in Institutional Development Award (IDeA) states. --Build pediatric research capacity for IDeA states to support the conduct of clinical trials of relevance to rural or underserved children in IDeA states.
Funding Opportunity RFA-NS-19-038 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-15-009. This Funding Opportunity Announcement (FOA) invites applications to support the National Institute of Neurological Disorders and Stroke (NINDS) Human Cell and Data Repository (NHCDR). The repository will maintain the current collection of fibroblast and induced pluripotent stem cell (iPSC) lines as well as develop, characterize, expand source cells and iPSCs, and where appropriate, genetically modify new high-quality iPSC lines accordance with the NINDS mission. The NINDS Human Cell and Data Repository will distribute human cell resources broadly to qualified academic and industry researchers to advance basic and translational research in neurological disorders.
Funding Opportunity RFA-DK-19-019 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks US domestic research projects that address how food insecurity effects HIV comorbidities, coinfections, and complications (CCCs) within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions that alleviate food insecurity improve CCCs. These mechanisms could be related to nutritional inadequacies or patient health-related behaviors.
Funding Opportunity RFA-RM-19-013 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support a Multisite Clinical Center to implement the enrollment and multimodal longitudinal assessment of a large cohort of patients that EITHER experienced an acute musculoskeletal trauma OR an acute peri-operative pain event to identify a biosignature for resilience to and/or the transition from acute to chronic pain.
Notice NOT-EB-19-016 from the NIH Guide for Grants and Contracts
Notice NOT-EB-19-017 from the NIH Guide for Grants and Contracts
Notice NOT-EB-19-015 from the NIH Guide for Grants and Contracts
Notice NOT-DA-19-066 from the NIH Guide for Grants and Contracts
Notice NOT-EB-19-018 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-070 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-358 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.
Funding Opportunity PAR-19-359 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.
Funding Opportunity PAR-19-360 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.
Notice NOT-AR-20-004 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-355 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.
Funding Opportunity PAR-19-352 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.
Funding Opportunity PAR-19-361 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to establish research teams of the Small-Cell Lung Cancer (SCLC) Consortium to conduct research whose overall goals are: 1) to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy. This FOA focuses on two of the five research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Small Cell Lung Cancer (SCLC). Additional priorities of the Framework are stated in this FOA, as studies are expected to use or develop state-of-the-art research tools and omic profiles to identify therapeutic strategies that are relevant to human SCLC disease progression and resistance. The research supported by this FOA will be performed by individual research teams who are expected to collaborate with one another and with a central SCLC Coordinating Center. A third component of the SCLC Consortium focuses on prevention and early detection of SCLC.
Funding Opportunity PAR-19-356 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).